Great West Life Assurance Co. Can cut its stake in PetMed Express, Inc. (NASDAQ:PETS) by 6.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,118 shares of the company’s stock after selling 2,000 shares during the quarter. Great West Life Assurance Co. Can owned 0.13% of PetMed Express worth $903,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. acquired a new position in shares of PetMed Express in the 3rd quarter valued at approximately $534,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of PetMed Express in the 3rd quarter valued at approximately $149,000. Dynamic Technology Lab Private Ltd grew its position in shares of PetMed Express by 116.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 21,925 shares of the company’s stock valued at $727,000 after purchasing an additional 11,782 shares during the period. Macquarie Group Ltd. acquired a new position in shares of PetMed Express in the 3rd quarter valued at approximately $577,000. Finally, Ameriprise Financial Inc. grew its position in shares of PetMed Express by 48.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 285,835 shares of the company’s stock valued at $9,474,000 after purchasing an additional 93,699 shares during the period. 99.88% of the stock is owned by institutional investors.

In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $35.57, for a total transaction of $35,570.00. Following the completion of the transaction, the director now owns 73,833 shares of the company’s stock, valued at approximately $2,626,239.81. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $44.38, for a total value of $887,600.00. Following the transaction, the director now directly owns 55,900 shares of the company’s stock, valued at approximately $2,480,842. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

PetMed Express, Inc. (NASDAQ:PETS) opened at $45.64 on Friday. PetMed Express, Inc. has a 12-month low of $19.21 and a 12-month high of $50.90. The firm has a market capitalization of $935.05, a P/E ratio of 30.63, a price-to-earnings-growth ratio of 2.73 and a beta of 1.13.

PetMed Express (NASDAQ:PETS) last released its quarterly earnings results on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. The firm had revenue of $66.70 million during the quarter, compared to the consensus estimate of $63.41 million. During the same quarter in the prior year, the firm posted $0.24 EPS. The business’s revenue was up 9.7% on a year-over-year basis. equities research analysts predict that PetMed Express, Inc. will post 1.68 earnings per share for the current year.

Several equities analysts recently issued reports on the company. BidaskClub upgraded PetMed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. Noble Financial reiterated a “hold” rating on shares of PetMed Express in a research report on Friday, October 27th. Zacks Investment Research upgraded PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a research report on Friday, October 20th. ValuEngine lowered PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Credit Suisse Group reiterated an “underperform” rating and issued a $19.00 price objective on shares of PetMed Express in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. PetMed Express has a consensus rating of “Hold” and a consensus price target of $42.00.

COPYRIGHT VIOLATION NOTICE: “PetMed Express, Inc. (PETS) Stake Lowered by Great West Life Assurance Co. Can” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/24/petmed-express-inc-pets-stake-lowered-by-great-west-life-assurance-co-can.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.